A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs PLX 7486 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Plexxikon
- 19 Mar 2018 Status changed from active, no longer recruiting to discontinued.
- 20 Sep 2017 Planned End Date changed from 1 Aug 2021 to 1 Dec 2018.
- 20 Sep 2017 Planned primary completion date changed from 1 Feb 2021 to 1 Dec 2018.